December 22, 2021
2 min watch
Save
VIDEO: Bomedemstat treatment for essential thrombocythemia
In this video, Aaron T. Gerds, MD, MS, discussed treatment findings from a phase two study presented at ASH Annual Meeting and Exposition.
The trial investigated the LSD1 inhibitor IMG-7289, or bomedemstat, as treatment for essential thrombocythemia.
“This, as a cytoreductive agent, is a very active compound,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.
Reference
- Palandri F, et al. Abstract 386. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.
Read more about